LENZ Therapeutics Q1 net loss $14.6M; LNZ100 PDUFA on track for Aug 8, 2025

LENZ Therapeutics, Inc.

2025-Q1 EPS reported -$0.53

Net loss $14.6M ($0.53 per share) vs $16.6M ($3.53) YoY; R&D down to $5.8M, SG&A up to $11.1M.
Cash $194.1M at Mar 31, 2025; anticipated balance >$185M at PDUFA; runway to post-launch positive cash flow.
NDA for LNZ100 (aceclidine eye drop for presbyopia) on track; FDA PDUFA target date Aug 8, 2025.
US Customs rulings confirm LNZ100 US origin and duty free, eliminating tariff exposure.
Pre-commercial hiring of 88 sales reps targeted by Jul 1, 2025; raised $16.3M net from April ATM block trade.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.